Study of the Safety & Tolerability of IV Infused PG545 in Patients With

Clinical Trial Summary

This Phase Ia study aims to establish the maximum tolerated dose of once-weekly IV infused PG545 and to evaluate its safety in subjects with advanced solid tumours. In addition, the study will explore whether PG545 exposure results in changes to chemicals produced by the body that are associated with cancer growth and spread.

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05514132` - A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours	Phase 1
Terminated	`NCT04949425` - A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours	Phase 1
Not yet recruiting	`NCT05537051` - A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours	Phase 1
Completed	`NCT02579226` - A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.	Phase 1
Terminated	`NCT01668550` - A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours	Phase 1
Completed	`NCT01058538` - A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours	Phase 1/Phase 2
Completed	`NCT02588105` - Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer	Phase 1
Recruiting	`NCT03852823` - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours	Phase 1
Not yet recruiting	`NCT06380816` - A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT01585701` - Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	Phase 1
Completed	`NCT03101839` - Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours	Phase 1
Completed	`NCT03150368` - Extended Use of ModraDoc006/r	Phase 1
Active, not recruiting	`NCT02389842` - PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib	Phase 1
Terminated	`NCT01581060` - Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours	Phase 1/Phase 2
Terminated	`NCT04959266` - A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib	Phase 1
Completed	`NCT04462952` - Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours	Phase 1
Active, not recruiting	`NCT03518606` - Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours	Phase 1/Phase 2
Completed	`NCT02430311` - The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.	Phase 1
Terminated	`NCT01859351` - Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours	Phase 1
Completed	`NCT01163903` - Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours	Phase 1

NCT number	NCT02042781
Study type	Interventional
Source	Zucero Pty Ltd
Contact
Status	Completed
Phase	Phase 1
Start date	January 2014
Completion date	September 2016

Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms